RLM.L Regulatory News (RLM)

24 Jul 2007 09:32

PuriCore Plc24 July 2007 24 July 2007 Notification of Director's Interest MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 24 July 2007- PuriCore (LSE: PURI), thelife sciences company focused on the development and commercialisation of itsnovel, safe antimicrobial technology, today announces that that on 23 July 2007the following Director purchased shares in the Company, as set out below: Name Number of ordinary Purchase Price of Total number of % of issued share shares purchased ordinary shares ordinary shares capital heldMike Sapountzoglou 25,000 48p 75,000 0.05% Contacts: PuriCore plc +1 (484) 321 2700Greg Bosch, Chief Executive OfficerKeith A. Goldan, Chief Financial Officer Financial Dynamics +44 (0) 20 7831 3113Ben BrewertonJohn Gilbert About PuriCore PuriCore (London Stock Exchange: PURI) is a life sciences company focused ondeveloping and commercialising proprietary products that safely, effectively,and naturally kill contagious pathogens. PuriCore's technology provides asolution to a broad range of markets that depend upon controlling contamination,including food safety, medical device disinfection, wound management, andhospitality. The Company's proprietary technology mimics the human body'sproduction of the natural antimicrobial hypochlorous acid, which is highlyeffective in killing bacteria, viruses, and fungal spores. Deployinghypochlorous acid solutions as soaks, sprays, mists, and in other forms,PuriCore's technology is designed to limit the spread of infectious disease,including major public health threats of M. tuberculosis, MRSA, E.coli,norovirus, avian influenza, HIV, polio virus, Helicobater pylori, andLegionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices inStafford, UK. To receive additional information on PuriCore, please visit our web site atwww.puricore.com, which does not form part of this press release. This information is provided by RNS The company news service from the London Stock Exchange